Last reviewed · How we verify
NCT03843593
A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery
trial testing Demographics Questionnaire in Cutaneous Melanoma in 38 participants. Completed in 29 December 2022.
29 December 2022
Quick facts
| Lead sponsor | Memorial Sloan Kettering Cancer Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 38 |
| Start date | 14 February 2019 |
| Primary completion | 29 December 2022 |
| Estimated completion | 29 December 2022 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- Demographics Questionnaire
- Adjuvant Treatment Beliefs Scale10
- Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11
- Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General (FACIT-TS-G)13
- Decisional Regret14
- Clinician Preference for Treatment
Conditions studied
- Cutaneous Melanoma — all drugs for Cutaneous Melanoma →
Sponsor
Memorial Sloan Kettering Cancer Center — full company profile →
Who can join
18 and older, any sex, with Cutaneous Melanoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to find out what patients consider when deciding whether or not to receive adjuvant treatment, and how patients feel about their decision after one year.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03843593
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Demographics Questionnaire
Trials testing the same drug.
- NCT04205786 — Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer · NA · withdrawn
Other recruiting trials for Cutaneous Melanoma
Currently open trials in the same condition.
- NCT06319196 — Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma · Phase 2 · recruiting
- NCT07148245 — Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma · recruiting
- NCT06984328 — Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin · Phase 2 · active not recruiting
- NCT06967961 — Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers · NA · recruiting
- NCT06194929 — Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutan · Phase 1, PHASE2 · recruiting
Other Memorial Sloan Kettering Cancer Center trials
Trials by the same sponsor.
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
- NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
- NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
- NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03843593 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
- Last refreshed: 4 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03843593.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing